HC Wainwright Reaffirms “Buy” Rating for Apellis Pharmaceuticals (NASDAQ:APLS)

HC Wainwright reissued their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a report issued on Monday morning, Benzinga reports. They currently have a $92.00 target price on the stock.

Several other research analysts have also issued reports on the stock. Mizuho reiterated a neutral rating and issued a $60.00 target price on shares of Apellis Pharmaceuticals in a research report on Wednesday, March 27th. Raymond James upped their target price on shares of Apellis Pharmaceuticals from $67.00 to $106.00 and gave the stock a strong-buy rating in a research report on Thursday, January 11th. Robert W. Baird reiterated an outperform rating and issued a $81.00 target price on shares of Apellis Pharmaceuticals in a research report on Tuesday, February 6th. JPMorgan Chase & Co. upped their target price on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an overweight rating in a research report on Wednesday, March 6th. Finally, Needham & Company LLC reiterated a buy rating and issued a $85.00 target price on shares of Apellis Pharmaceuticals in a research report on Tuesday, April 9th. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of Moderate Buy and an average price target of $78.60.

Apellis Pharmaceuticals Stock Down 0.6 %

APLS opened at $51.50 on Monday. The company has a fifty day moving average price of $61.22 and a 200-day moving average price of $57.00. The firm has a market capitalization of $6.21 billion, a P/E ratio of -11.50 and a beta of 0.88. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.10 and a quick ratio of 2.50. Apellis Pharmaceuticals has a one year low of $19.83 and a one year high of $94.75.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.73) EPS for the quarter, meeting analysts’ consensus estimates of ($0.73). The firm had revenue of $146.38 million during the quarter, compared to analyst estimates of $143.34 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The business’s revenue for the quarter was up 545.9% on a year-over-year basis. During the same period in the previous year, the business earned ($1.50) EPS. Equities research analysts expect that Apellis Pharmaceuticals will post -1.33 earnings per share for the current fiscal year.

Insider Activity

In other news, CAO James George Chopas sold 1,061 shares of the company’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $65.00, for a total transaction of $68,965.00. Following the completion of the transaction, the chief accounting officer now directly owns 39,067 shares of the company’s stock, valued at $2,539,355. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CAO James George Chopas sold 1,061 shares of the company’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $65.00, for a total transaction of $68,965.00. Following the completion of the transaction, the chief accounting officer now directly owns 39,067 shares of the company’s stock, valued at $2,539,355. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, General Counsel David O. Watson sold 4,184 shares of the company’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $65.00, for a total transaction of $271,960.00. Following the transaction, the general counsel now directly owns 105,077 shares of the company’s stock, valued at $6,830,005. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 406,651 shares of company stock valued at $25,130,257. Insiders own 7.50% of the company’s stock.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of institutional investors have recently bought and sold shares of APLS. Bank of New York Mellon Corp raised its stake in Apellis Pharmaceuticals by 5.8% in the first quarter. Bank of New York Mellon Corp now owns 315,480 shares of the company’s stock worth $16,029,000 after buying an additional 17,287 shares in the last quarter. American Century Companies Inc. bought a new position in Apellis Pharmaceuticals in the first quarter worth about $820,000. US Bancorp DE raised its stake in Apellis Pharmaceuticals by 391.2% in the first quarter. US Bancorp DE now owns 1,110 shares of the company’s stock worth $56,000 after buying an additional 884 shares in the last quarter. MetLife Investment Management LLC raised its stake in Apellis Pharmaceuticals by 67.0% in the first quarter. MetLife Investment Management LLC now owns 41,293 shares of the company’s stock worth $2,098,000 after buying an additional 16,567 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in Apellis Pharmaceuticals by 5.2% in the first quarter. Rhumbline Advisers now owns 77,764 shares of the company’s stock worth $3,951,000 after buying an additional 3,835 shares in the last quarter. 96.29% of the stock is owned by institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).